Radha Kodiappan

Radha Kodiappan

Auto-generated profile, based on publicly available information

Radha Kodiappan

Perdana University-Royal College of Surgeons in Ireland, Perdana University, Jalan MAEPS Perdana, Serdang, Selangor Darul Ehsan, Malaysia; Medical Genetics Laboratory, Genetics & Regenerative Medicine Research Centre, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor Darul Ehsan, Malaysia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cytotherapy
Verified
Journal Article
Closed access
SVShalini Vellasamy
Shalini Vellasamy
CTChih Kong Tong
Chih Kong Tong
NANur Atiqah Azhar
Nur Atiqah Azhar
RKRadha Kodiappan
Radha Kodiappan
SCSoon-Choy Chan
Soon-Choy Chan
RRRajesh Ramasamy
Rajesh Ramasamy

31 December 2017 in International Journal of Stem cell Research & Therapy
Verified
Journal Article
Open access
GSGounder Sellamuthu Subbanna
Gounder Sellamuthu Subbanna
KRKodiappan Radha
Kodiappan Radha
CCChan Soon Choy
Chan Soon Choy
AVAbhi Veerakumarasivam
Abhi Veerakumarasivam
SBSubramani Baskar
Subramani Baskar
Liver cirrhosis is a leading cause of mortality worldwide. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation.

1 October 2014 in Cancer Research
Verified
Journal Article
Closed access
AVAbhimanyu Veerakumarasivam
Abhimanyu Veerakumarasivam
RKRadha Kodiappan
Radha Kodiappan
SCSoon Choy Chan
Soon Choy Chan
ARAzad Hassan Abdul Razack
Azad Hassan Abdul Razack
TOTeng Aik Ong
Teng Aik Ong
We recently identified KDM5B as a putative oncogene. The expression of KDM5B correlated with increased cellular proliferative capacity and was found to be overexpressed in many cancers including bladder cancer (BC). KDM5B is a histone demethylase enzyme that modifies chromatin structure to specify cellular transcriptional states. It is a cancer/testis antigen; whereby in normal conditions, expression is limited to early embryonic stages and the testis in adults. Thus, KDM5B is an excellent therapeutic target. Since the expression of KDM5B in embryonic stem cells is orchestrated by miRNAs and that the expression of miRNAs are altered in BC, we hypothesized that miRNAs may be the switch that can abate the expression of KDM5B and thus affect the malignant phenotype of BC cells. This study was aimed at identifying and modulating the expression of miRNAs that are able to regulate KDM5B expression and BC phenotypes. By coupling in silico screens with RT-QPCR analysis of in vitro expression of BC cells of different malignant potential, we predicted several miRNAs as potential regulators of KDM5B transcripts. The functional effects of specific miRNAs on KDM5B expression, cell cycle, proliferation and invasion of BC cells was determined by modulating the expression of these miRNAs using mimics (upregulation) and antagomirs (downregulation). Expression of miR-137 in BC cells was found to be inversely correlated with KDM5B expression. Ectopic overexpression of miR-137 led to the repression of KDM5B expression, reduced cell growth and invasion as well as increased apoptosis of BC cells. In contrast, the downregulation of miR-137 expression led to reverse effects. The expression modulation of miR-137 also affected the expression of other BC-associated genes such as JDP2 and EGR2. While our results suggest that miR-137 can mitigate the KDM5B-associated BC phenotype, further studies on understanding the effect on aberrant histone methylation patterns are warranted. Citation Format: Abhimanyu Veerakumarasivam, Radha Kodiappan, Soon Choy Chan, Azad Hassan Abdul Razack, Teng Aik Ong. microRNA-mediated loss of KDM5B expression leads to suppression of the malignant bladder cancer phenotype. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5213. doi:10.1158/1538-7445.AM2014-5213